- Zoomtopia 2023: One platform delivering limitless human connection
- Hyderabad man dies in US after falling into swimming pool
- NMC believes that Union should not represent matter, ASG tells Delhi HC in stem cell therapy for autism case
- Sri Lanka varsity drops joint research with Chinese ship Shi Yan 6 despite pressure from Beijing
- Assam to conduct socio-economic survey of five 'indigenous' Muslim communities
- Bajaj Allianz gets Rs 1,010 crore GST demand notice
- Asian Games: Parul Choudhary, Annu Rani claim gold as India picks six medals in athletics
- Delhi HC defers Kal Airways' Kalanithi Maran's plea against SpiceJet CMD to Oct 9
- Maruti Suzuki gets Income Tax Dept order to pay up Rs 2,159cr
- Manipur CM announces reward on absconding ‘rumour monger’
Treatment for obesity, fatty liver disease in the offing
Scientists say they have discovered 27 new molecules with the potential to treat fatty liver disease, obesity, diabetic nephrotoxicity, as well as heal wounds
Jerusalem: Scientists say they have discovered 27 new molecules with the potential to treat fatty liver disease, obesity, diabetic nephrotoxicity, as well as heal wounds.
These molecules activate a special protein called PPAR-delta, said researchers from the Hebrew University of Jerusalem in Israel. Scientists developed an algorithm that sifted through a database of 1.56 million molecules and picked out 27 with a strong therapeutic potential, as determined by biologists at the Novartis Genomic (GNF) Institute in San Diego, US.
The molecules, described in the journal Scientific Reports, are undergoing pharmaceutical evaluations to treat two main health conditions. The first is fatty liver disease, also known as NASH (non-alcoholic steatoheptatis), researchers said. This disease currently has no cure and is a leading cause of liver cancer in the western world, they said. The second is obesity. PPAR-delta activation has the potential to increase physical endurance and trim waistlines by getting muscle cells to burn more fat, according to researchers.
Future evaluations will hopefully include testing treatments for improved wound healing, and to prevent kidney toxicity in diabetics. "With such a large group of highly active molecules, there is a high probability to find treatments for several common diseases. "However, we should wait till all the experiments are done before we get our hopes up too high," said Professor Amiram Goldblum from the Hebrew University. Diabetic nephropathy is a vascular complication of diabetes that requires preventive strategies focused on controlling blood pressure.
Integra Holdings, Hebrew University's biotech company, determined that 21 of the 27 molecules have the potential to reach pharmaceutical success, especially as a possible cure for fatty liver disease. Israel's Heller Institute of Medical Research is currently testing PPAR-delta's physical endurance properties on mice. Goldblum predicts that in a few years we will hopefully be seeing several of these molecules in the pipeline for clinical studies on humans.